DOI: 10.1055/s-00000133

Gastroenterologie up2date

References

Blanke CD, Demetri GD, Mehren M von. et al.
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. 
J Clin Oncol 2008; 26: 620-625  

Download Bibliographical Data

Search in:
Access:
Access: